<DOC>
	<DOCNO>NCT01873729</DOCNO>
	<brief_summary>The primary aim study ass whether naltrexone monotherapy effective treat Attention Deficit Hyperactivity Disorder ( ADHD ) adult . Medications increase dopamine often effective treat ADHD adult . Since naltrexone kappa opioid receptor antagonist , increase dopamine brain . We predict naltrexone monotherapy effective ADHD symptom adult ADHD .</brief_summary>
	<brief_title>An Open-Label Study Naltrexone Adults With Attention Deficit Hyperactivity Disorder .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion Criteria Male female outpatient 1855 year age . Diagnosis ADHD , DSMIV clinical evaluation expert clinician . Subjects treat anxiety disorder depression stable medication regimen least one month , disorderspecific CGISeverity score â‰¤ 3 ( mildly ill ) score HamiltonDepression HamiltonAnxiety rating scale 15 ( mild range ) . Exclusion Criteria Any clinically unstable psychiatric condition include history psychosis mania , suicidality , sociopathy , criminality , delinquency . Current ( last 3 month ) substance use disorder ( alcohol drug ) , Medical condition treatment either jeopardize subject safety affect scientific merit study include cardiovascular disease , current untreated hypertension , history renal hepatic impairment , condition may require treatment opioid analgesic . Clinically significant abnormal baseline laboratory LFT 's , define LFT 's great ULN . Mental retardation ( IQ &lt; 80 ) . Organic brain disorder include delirium , dementia , seizure , stroke , neurosurgery , head trauma loss consciousness . Pregnant nursing female . Subjects current adequate treatment ADHD . Current treatment medication ADHD . Any concomitant medication primarily central nervous system activity specify protocol ( stable effective treatment regimen SSRI benzodiazepine permit per clinical review . ) A Clinical Global Impression ( CGI ) 7 ( among extremely ill patient ) screen visit exclusionary , subject present CGIS 7 point study remove participation . Subjects present CGISeverity score 6 ( severely ill ) two consecutive visit week 2 drop study ( i.e . A subject CGI 6 his/her week 3 visit week 4 visit drop study week 4 visit ) . Subjects drop severe worsen symptom exposure study medication receive free follow care describe detailed protocol protocol summary . NonEnglish speaking subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>Adults</keyword>
</DOC>